Hepatitis B nursing reference: pathophysiology, assessment, and interventions

Hepatitis B is a blood-borne viral infection that inflames and damages the liver, and it remains one of the most clinically significant infectious diseases you will encounter across med-surg, ICU, emergency, and community health rotations. Globally, more than 250 million people live with chronic hepatitis B virus (HBV) infection, and in the United States, an estimated 880,000 to 1.4 million people are chronically infected — many without a diagnosis. What makes HBV challenging for nursing students is the complexity of its serology panel: understanding which markers indicate active infection, immunity, or chronic disease is tested on the NCLEX and essential for safe clinical practice.

This reference covers HBV from the nursing perspective: pathophysiology, serology interpretation, clinical presentation, nursing assessment and lab values, antiviral treatment, nursing interventions, complications, and patient education. For downstream hepatic complications, pair this with the cirrhosis nursing reference and the liver failure nursing reference.

HBV serology quick reference

The serology panel is the most NCLEX-tested aspect of hepatitis B. Memorize these markers — the pattern of positives and negatives tells you exactly where the patient is in the infection timeline.

Key serology patterns to know:

• Susceptible (never infected, unvaccinated): HBsAg negative, anti-HBs negative, anti-HBc negative
• Acute infection: HBsAg positive, anti-HBc IgM positive, anti-HBs negative
• Chronic infection: HBsAg positive for >6 months, anti-HBc IgG positive, anti-HBs negative
• Resolved infection: HBsAg negative, anti-HBs positive, anti-HBc IgG positive
• Vaccinated (immune): HBsAg negative, anti-HBs positive, anti-HBc negative

Pathophysiology

HBV is a partially double-stranded DNA virus. It is not directly cytopathic — the liver damage in hepatitis B is driven primarily by the host immune response, not the virus killing hepatocytes outright.

Acute infection

After exposure, HBV enters the bloodstream and travels to the liver, where it infects hepatocytes. The incubation period is 45–180 days (average around 75 days). During this time, HBsAg becomes detectable in serum, often weeks before symptoms appear. As the immune system mounts a CD8+ T-cell response against infected hepatocytes, liver inflammation and cell necrosis follow. In immunocompetent adults, approximately 95% of acute HBV infections resolve spontaneously within 6 months. The immune response clears the virus, HBsAg disappears, and anti-HBs develops, conferring lifelong immunity.

A small proportion of adults with acute HBV develop fulminant hepatic failure — a life-threatening complication where massive hepatocyte necrosis overwhelms the liver’s regenerative capacity. Signs include rapidly worsening jaundice, coagulopathy, and hepatic encephalopathy, and these patients require emergent evaluation for liver transplant.

Chronic infection

Chronic hepatitis B is defined as HBsAg persistence beyond 6 months. The risk of chronicity is strongly age-dependent:

• Neonates infected perinatally: ~90% progress to chronic infection
• Children aged 1–5: ~30%
• Adults: ~5%

This inverts the clinical rule: infants tolerate the virus without mounting an effective immune response, so the virus persists; adults mount a robust response and clear it. But that immune response in adults is also what causes most of the acute liver damage.

In chronic infection, ongoing immune-mediated hepatocyte destruction causes cycles of inflammation, necrosis, and attempted regeneration. Over years to decades, this fibrosis and nodular regeneration remodel hepatic architecture into cirrhosis. The degree of ongoing viral replication (measured by HBV DNA and HBeAg status) influences the rate of fibrotic progression.

HBV’s replication mechanism — using reverse transcriptase to copy its genome — creates a stable intrahepatic reservoir of covalently closed circular DNA (cccDNA). This reservoir persists inside hepatocyte nuclei even when surface antigen is undetectable, which is why current antivirals suppress but rarely cure HBV: they target reverse transcription but cannot eliminate cccDNA.

Transmission and epidemiology

HBV is transmitted through percutaneous, mucosal, or nonintact skin exposure to infectious blood, semen, or other body fluids. The virus can survive on surfaces for up to 7 days — a detail relevant to infection control on your unit.

Primary transmission routes:

• Perinatal: Mother-to-infant transmission during birth — the most common route globally, and the most efficient. Without prophylaxis, an HBeAg-positive mother transmits HBV to ~90% of neonates.
• Sexual contact: Unprotected sex with an infected partner. HBV is 50–100 times more infectious than HIV via sexual transmission.
• Blood exposure: Needle sharing, needlestick injuries, blood transfusions (now rare in screened blood supply), tattooing or piercing with unsterile equipment.
• Horizontal transmission: Household contact — sharing razors, toothbrushes, glucose monitoring equipment, or nail clippers.

HBV is not transmitted through casual contact: hugging, sharing food or water, sneezing, coughing, or breastfeeding (absent nipple cracking or blood exposure).

High-risk groups include people who inject drugs, men who have sex with men, household and sexual contacts of HBV-infected individuals, healthcare workers with occupational exposures, and individuals born in countries with intermediate-to-high HBV endemicity (sub-Saharan Africa, East Asia, the Pacific Islands, and parts of Eastern Europe).

Clinical presentation

Acute hepatitis B

The majority of adults with acute HBV infection are symptomatic, though symptoms range from mild to severe. Onset is typically gradual.

Prodromal phase (1–2 weeks before jaundice):

• Fatigue, malaise, anorexia, nausea, vomiting
• Low-grade fever
• Right upper quadrant discomfort
• Arthralgias, myalgias (immune complex deposition)
• Urticaria or rash (less common)

Icteric phase (when bilirubin rises enough for jaundice):

• Jaundice — yellow sclera is often the first visible sign; skin yellowing follows
• Dark urine (bilirubinuria — resembles iced tea or cola)
• Pale or clay-colored stools (bilirubin diverted away from gut)
• Pruritus (bile salt deposition in skin)
• Hepatomegaly with right upper quadrant tenderness on palpation
• Splenomegaly in some cases

Chronic hepatitis B

Most people with chronic HBV are asymptomatic for years to decades. When symptoms appear, they often reflect advancing liver disease rather than active viral replication:

• Persistent fatigue (the most common complaint)
• Intermittent right upper quadrant discomfort
• Arthralgias
• Signs of portal hypertension and cirrhosis in advanced disease: ascites, spider angiomas, palmar erythema, gynecomastia in men, caput medusae

Many patients are diagnosed incidentally — via prenatal screening, blood donation testing, or routine labs — rather than for symptomatic illness.

Nursing assessment and lab values

History and physical assessment

When you assess a patient with known or suspected HBV:

• Exposure history: IV drug use, sexual contacts, country of birth, occupational exposures, tattoos/piercings
• Vaccination history: Verify completed 3-dose series
• Vital signs: Fever may indicate acute infection or superimposed infection
• Abdominal assessment: Hepatomegaly (palpable liver edge >2 cm below costal margin), tenderness in the right upper quadrant, splenomegaly; assess for ascites with fluid wave and shifting dullness
• Skin and sclera: Jaundice (scleral icterus is usually visible before skin yellowing), spider angiomas, palmar erythema, ecchymoses
• Urine and stool color: Dark urine, pale stools
• Neurological: Mental status changes — confusion or asterixis signal hepatic encephalopathy if liver function deteriorates

Lab values

For the full lab interpretation framework, see the nursing lab values cheat sheet.

Priority assessment findings that require immediate escalation

Call the provider immediately for:

• Altered mental status, confusion, or asterixis (flapping tremor) in a patient with liver disease
• INR >1.5 and rapidly worsening in acute hepatitis — suggests fulminant failure
• GI bleeding: hematemesis, melena, or bright red blood per rectum
• Hypotension with jaundice
• Hypoglycemia — the liver’s gluconeogenic capacity is failing

Treatment and pharmacology

Acute hepatitis B

Acute HBV in immunocompetent adults does not require antiviral therapy in most cases — the immune system clears the infection. Management is supportive:

• Rest and adequate hydration
• Nutritional support: small, frequent meals; high-carbohydrate, low-fat diet often tolerated better during nausea
• Avoid alcohol entirely
• Avoid hepatotoxic medications — acetaminophen should be used cautiously or avoided; NSAIDs carry bleeding and renal risks in liver disease
• Monitor LFTs, INR, and bilirubin regularly to detect progression toward fulminant failure

Antivirals are considered for acute severe HBV (prolonged INR, significant jaundice, severe symptoms) in consultation with hepatology.

Chronic hepatitis B — antiviral treatment

Not all patients with chronic HBV require treatment. Treatment is indicated based on ALT levels, HBV DNA viral load, HBeAg status, and degree of fibrosis. Current first-line antiviral agents:

Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)

• Nucleotide reverse transcriptase inhibitors
• High barrier to resistance — preferred first-line agents
• TDF nursing considerations: monitor renal function (creatinine, eGFR, urine phosphate) and bone density with long-term use; TAF has a more favorable renal and bone safety profile
• Pregnancy: TDF is safe and preferred in pregnancy; commonly used to reduce perinatal transmission in mothers with high viral loads

Entecavir

• Nucleoside reverse transcriptase inhibitor
• Also a first-line agent with high barrier to resistance
• Nursing considerations: renal dose adjustment required; avoid in patients with lamivudine resistance

Pegylated interferon alfa-2a (Peg-IFN)

• Immunomodulatory — finite treatment course (48 weeks), potential for HBsAg loss (functional cure) in some patients
• Nursing considerations: significant side effect profile — flu-like symptoms, depression, neutropenia, thrombocytopenia; contraindicated in decompensated cirrhosis, autoimmune disease, pregnancy
• Requires close monitoring of CBC, thyroid function, and mood

Key principle: antivirals suppress HBV replication but rarely eradicate it due to the cccDNA reservoir. Patients typically require long-term therapy. Abrupt discontinuation can cause a severe hepatitis flare — this is a critical patient education point.

Nursing interventions

Monitoring

• Assess vital signs and temperature — fever in a patient with chronic liver disease may signal spontaneous bacterial peritonitis or other infection
• Monitor LFTs, INR, and bilirubin trending — document and report worsening values promptly
• Track daily weights and fluid balance — fluid retention (ascites, edema) indicates portal hypertension and hypoalbuminemia
• Monitor abdominal girth in patients with known or suspected ascites
• Assess for bleeding: inspect skin for ecchymoses, check stool and urine for blood, note gum bleeding or prolonged oozing from venipuncture sites

Infection control

HBV is a blood-borne pathogen. Apply standard precautions for all patients; contact precautions are not required for HBV beyond standard precautions when there is no active bleeding or wound drainage.

For healthcare workers:

• Vaccination is the primary protection — confirm your HBV vaccination series is complete and verify immunity with anti-HBs titer
• Use needleless IV systems and safety-engineered sharps devices
• Report all needlestick and blood exposure incidents immediately for post-exposure prophylaxis assessment

Vaccination and post-exposure prophylaxis

Standard vaccination series: Three doses — at 0, 1, and 6 months. A two-dose series (Heplisav-B, given 1 month apart) is also approved for adults. Immunity is confirmed by anti-HBs titer ≥10 mIU/mL one to two months after completing the series.

Post-exposure prophylaxis (PEP): When an unvaccinated or incompletely vaccinated person has a significant HBV exposure (needlestick, sexual contact with HBsAg-positive individual, perinatal exposure):

• Hepatitis B immune globulin (HBIG): Provides immediate passive immunity. Must be given as soon as possible — ideally within 12–24 hours, and no later than 7 days after percutaneous exposure or 14 days after sexual exposure.
• Hepatitis B vaccine: Start or complete the vaccination series at the same time as HBIG (at a separate injection site).
• Neonates of HBsAg-positive mothers: HBIG and the first vaccine dose given within 12 hours of birth — reduces perinatal transmission by ~95%.

Comfort and symptom management

• Pruritus: cool baths, loose cotton clothing, emollient moisturizers; report severe pruritus — cholestyramine may be prescribed
• Nausea: small frequent meals; offer bland, easily digested foods; administer antiemetics as prescribed
• Fatigue: cluster nursing care to allow rest periods; educate on energy conservation; validate that fatigue is a real and expected symptom
• Skin integrity: inspect jaundiced skin; patients with elevated bilirubin are at risk for skin breakdown from scratching

Patient education priorities

1. Transmission prevention: HBV spreads through blood, sexual contact, and perinatal exposure — not through hugging, sharing food, or casual household contact. Patients should not share razors, toothbrushes, nail clippers, glucose monitoring equipment, or injection supplies.
2. Household and sexual contact vaccination: All household members and sexual partners should be tested and vaccinated.
3. Alcohol: Avoid alcohol completely — it accelerates hepatic fibrosis and liver failure.
4. Medications: Review all medications including OTC and supplements for hepatotoxicity. Acetaminophen should be used only as directed and at the lowest effective dose, if at all.
5. Antiviral adherence: Never stop antivirals without talking to the provider — abrupt discontinuation can trigger a hepatitis flare that may cause acute liver failure.
6. Surveillance: Patients with chronic HBV require lifelong monitoring — HBV DNA, ALT, and HCC surveillance with liver ultrasound every 6 months.
7. Disclosure: Patients should inform sexual partners and healthcare providers (including dentists) of their HBV status.
8. Pregnancy: Women with chronic HBV planning pregnancy should discuss management with their provider — antiviral therapy may be indicated in the third trimester to reduce perinatal transmission.

Complications

Cirrhosis

The most common long-term complication of chronic HBV. Ongoing inflammation and fibrosis remodel hepatic architecture over years to decades. Risk is higher with persistent HBeAg positivity, high HBV DNA, coinfection with HDV or HCV, and alcohol use. See the cirrhosis nursing reference for detailed management.

Hepatocellular carcinoma (HCC)

Chronic HBV infection is the leading cause of hepatocellular carcinoma worldwide. HCC can develop in patients with chronic HBV even without cirrhosis — a distinction from hepatitis C, where HCC almost always develops on a background of cirrhosis. Annual or biannual liver ultrasound with AFP measurement is the standard surveillance strategy.

Fulminant hepatic failure

Rare but life-threatening complication of acute HBV. Massive hepatocyte necrosis overwhelms the liver’s regenerative capacity, resulting in coagulopathy, encephalopathy, and multi-organ failure. INR >1.5 with any encephalopathy in acute hepatitis defines acute liver failure. These patients require emergent hepatology and transplant evaluation. See the liver failure nursing reference.

Hepatitis D (HDV) coinfection

HBV is the only virus that can be coinfected or superinfected by hepatitis D virus (HDV), a defective RNA virus that requires HBsAg to replicate. HBV/HDV coinfection causes more severe acute hepatitis and accelerates progression to cirrhosis. HBV vaccination prevents HDV infection — a strong argument for universal HBV vaccination.

Extrahepatic manifestations

Immune complex deposition can cause extrahepatic disease in a small proportion of patients with chronic HBV: membranous nephropathy (glomerulonephritis), polyarteritis nodosa, and cryoglobulinemia. These are rare but worth recognizing.

Related references

This reference is part of the hepatic sub-pillar. For downstream complications, see:

• Cirrhosis nursing reference — Child-Pugh staging, ascites, varices, and hepatic encephalopathy management
• Liver failure nursing reference — acute vs. chronic failure, MELD scoring, ICU-level care
• Nursing lab values cheat sheet — complete LFT interpretation in context
• Electrolyte imbalances reference — hyponatremia, hypokalemia, and hypomagnesemia common in liver disease
• Drug classifications nursing reference — antiviral and immunomodulatory drug classes